Wegovy is made as a biologic medicine, meaning it uses recombinant technology to produce semaglutide, a protein-based drug. Mysimba and...

Yes — trials show Wegovy users lose more weight earlier than with Saxenda, thanks to its stronger appetite effect and weekly dosing. That...

Yes — trials show Wegovy users lose more weight earlier than with Saxenda, thanks to its stronger appetite effect and weekly dosing. That said, both require steady use over months for results to build. The two medicines at a glance Wegovy and Saxenda belong to the same family of medicines, GLP-1 receptor agonists. They help people feel fuller sooner, reduce appetite, and support healthier eating. The difference lies in the active ingredient and how they are dosed: Wegovy cont

Wegovy mimics the hormone GLP-1, acting on the brain to reduce appetite and slow digestion. Contrave (naltrexone/bupropion) affects brain...

Both Wegovy (semaglutide 2.4 mg) and Trulicity (dulaglutide) improve blood sugar, but semaglutide generally produces greater reductions...

Wegovy mimics the hormone GLP-1, acting on the brain to reduce appetite and slow digestion. Contrave (naltrexone/bupropion) affects brain reward and craving pathways, which can reduce emotional eating but doesn’t directly target satiety hormones. How Wegovy works Wegovy (semaglutide 2.4 mg weekly) is a GLP-1 receptor agonist. It mimics a natural gut hormone called GLP-1, which signals to the brain that you are full, slows down stomach emptying, and enhances insulin release wh

Both Wegovy (semaglutide 2.4 mg) and Trulicity (dulaglutide) improve blood sugar, but semaglutide generally produces greater reductions in HbA1c and body weight. NICE recommends semaglutide more widely for people needing weight-focused management. Two GLP-1 medicines, one key difference Wegovy and Trulicity both belong to the GLP-1 receptor agonist family of medicines. They mimic the hormone GLP-1, which reduces appetite, slows digestion, and stimulates insulin release when b

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other medicines have different risks: Orlistat can cause oily stools, Mysimba may raise blood pressure, and phentermine (not used in the UK) carries cardiovascular risks. Understanding risk in context All weight-loss medicines come with benefits and risks. Doctors weigh these carefully before prescribing, taking into account a person’s health conditio

Yes, Wegovy has strong evidence in people with type 2 diabetes, cardiovascular disease, and sleep apnoea, where weight loss can improve outcomes. Other drugs may be chosen if semaglutide is unsuitable, but few have shown the same range of benefits across multiple health conditions. Why certain conditions matter Weight-related health problems often go beyond the number on the scales. People with obesity are more likely to develop type 2 diabetes, cardiovascular disease, and sl

Yes, Wegovy has strong evidence in people with type 2 diabetes, cardiovascular disease, and sleep apnoea, where weight loss can improve...

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other...

The SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced the risk of major heart problems in people with overweight or obesity and...

No, even though both contain semaglutide, they are licensed for different uses and come in different devices and doses. Doctors may...

The SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced the risk of major heart problems in people with overweight or obesity and cardiovascular disease. Orlistat, while useful for modest weight loss, has not shown the same scale of cardiovascular benefits in large outcome studies. Two very different medicines Wegovy and Orlistat are both prescribed for weight management, but they work in completely different ways. Wegovy (semaglutide) is a GLP-1 receptor agonist that red

No, even though both contain semaglutide, they are licensed for different uses and come in different devices and doses. Doctors may...

In the UK, coverage depends on NHS commissioning rather than insurance, and NICE now recommends Wegovy within specialist services....

In the UK, coverage depends on NHS commissioning rather than insurance, and NICE now recommends Wegovy within specialist services. Saxenda has more limited NHS use. In private healthcare or in other countries, coverage varies by insurer, but newer guidance tends to prioritise Wegovy because of its stronger results. The UK context: NHS commissioning, not insurance Unlike in the United States, where health insurance policies determine which drugs are covered, the UK relies on t

Wegovy works directly on appetite signals in the brain, helping people feel full sooner and think less about food. Other medicines act...

Wegovy works directly on appetite signals in the brain, helping people feel full sooner and think less about food. Other medicines act...

Wegovy has shown sustained weight loss of around 15% at 68 weeks, and many participants maintained benefits at two years. Qsymia (not...